{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:53:13Z","timestamp":1785041593174,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shire Development LLC, a member of the Takeda group of companies, Lexington, MA, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40263-021-00808-x","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T14:38:42Z","timestamp":1618497522000},"page":"575-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit\/Hyperactivity Disorder: A Claims Database Analysis Across the USA"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8479-2775","authenticated-orcid":false,"given":"Sepehr","family":"Farahbakhshian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Ayyagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Barczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simerpal K.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kulalert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Spalding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"808_CR1","unstructured":"Centers for Disease Control and Prevention. Attention-deficit\/hyperactivity disorder fact sheet. 2020. https:\/\/www.cdc.gov\/ncbddd\/adhd\/facts.html. Accessed 11 May 2020."},{"key":"808_CR2","doi-asserted-by":"publisher","first-page":"e994","DOI":"10.1542\/peds.2014-3482","volume":"135","author":"R Thomas","year":"2015","unstructured":"Thomas R, Sanders S, Doust J, et al. Prevalence of attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;135:e994\u20131001.","journal-title":"Pediatrics"},{"key":"808_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biopsych.2008.10.005","volume":"65","author":"C Lara","year":"2009","unstructured":"Lara C, Fayyad J, de Graaf R, et al. Childhood predictors of adult attention-deficit\/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry. 2009;65:46\u201354.","journal-title":"Biol Psychiatry."},{"key":"808_CR4","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1001\/archgenpsychiatry.2010.146","volume":"67","author":"RC Kessler","year":"2010","unstructured":"Kessler RC, Green JG, Adler LA, et al. Structure and diagnosis of adult attention-deficit\/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale. Arch Gen Psychiatry. 2010;67:1168\u201378.","journal-title":"Arch Gen Psychiatry."},{"key":"808_CR5","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.biopsych.2005.04.001","volume":"57","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit\/hyperactivity disorder persistence into adulthood: results from the National Comorbidity Survey Replication. Biol Psychiatry. 2005;57:1442\u201351.","journal-title":"Biol Psychiatry."},{"key":"808_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ejpn.2012.01.009","volume":"16","author":"S Cortese","year":"2012","unstructured":"Cortese S. The neurobiology and genetics of attention-deficit\/hyperactivity disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol. 2012;16:422\u201333.","journal-title":"Eur J Paediatr Neurol."},{"key":"808_CR7","first-page":"893","volume":"4","author":"K Blum","year":"2008","unstructured":"Blum K, Chen AL, Braverman ER, et al. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat. 2008;4:893\u2013918.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"808_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S2215-0366(17)30049-4","volume":"4","author":"M Hoogman","year":"2017","unstructured":"Hoogman M, Bralten J, Hibar DP, et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. Lancet Psychiatry. 2017;4:310\u20139.","journal-title":"Lancet Psychiatry"},{"key":"808_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neubiorev.2018.02.001","volume":"87","author":"SV Faraone","year":"2018","unstructured":"Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit\/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255\u201370.","journal-title":"Neurosci Biobehav Rev."},{"key":"808_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1542\/peds.2011-2654","volume":"128","author":"M Wolraich","year":"2011","unstructured":"Wolraich M, Subcommittee on Attention-Deficit\/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007\u201322.","journal-title":"Pediatrics"},{"key":"808_CR11","unstructured":"National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline (NG87). London: 2018."},{"key":"808_CR12","unstructured":"Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines, 4.1 Edition. Toronto: CADDRA; 2020."},{"key":"808_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5:727\u201338.","journal-title":"Lancet Psychiatry"},{"key":"808_CR14","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJMra1917069","volume":"383","author":"S Cortese","year":"2020","unstructured":"Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med. 2020;383:1050\u20136.","journal-title":"N Engl J Med."},{"key":"808_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neubiorev.2017.11.007","volume":"84","author":"M Ruiz-Goikoetxea","year":"2018","unstructured":"Ruiz-Goikoetxea M, Cortese S, Aznarez-Sanado M, et al. Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;84:63\u201371.","journal-title":"Neurosci Biobehav Rev."},{"key":"808_CR16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1176\/ajp.2006.163.4.716","volume":"163","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716\u201323.","journal-title":"Am J Psychiatry."},{"key":"808_CR17","unstructured":"Pawaskar M, Witt EA, Ming EE, et al. Estimating the prevalence of DSM-5 attention deficit\/hyperactivity disorder (ADHD) in a community sample [P6-003]. American Psychiatric Association Annual Meeting; 16\u201320 May 2015; Toronto (ON)."},{"key":"808_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/mpr.167","volume":"13","author":"RC Kessler","year":"2004","unstructured":"Kessler RC, Berglund P, Chiu WT, et al. The US National Comorbidity Survey Replication (NCS-R): design and field procedures. Int J Methods Psychiatr Res. 2004;13:69\u201392.","journal-title":"Int J Methods Psychiatr Res."},{"key":"808_CR19","first-page":"1543","volume":"10","author":"K Gajria","year":"2014","unstructured":"Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit\/hyperactivity disorder: a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543\u201369.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"808_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jadohealth.2016.12.011","volume":"60","author":"MR Schaefer","year":"2017","unstructured":"Schaefer MR, Rawlinson AR, Wagoner ST, et al. Adherence to attention-deficit\/hyperactivity disorder medication during the transition to college. J Adolesc Health. 2017;60:706\u201313.","journal-title":"J Adolesc Health."},{"key":"808_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaac.2016.07.774","volume":"55","author":"L Hechtman","year":"2016","unstructured":"Hechtman L, Swanson JM, Sibley MH, et al. Functional adult outcomes 16 years after childhood diagnosis of attention-deficit\/hyperactivity disorder: MTA results. J Am Acad Child Adolesc Psychiatry. 2016;55:945\u201352.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"808_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12913-016-1509-0","volume":"16","author":"H Eklund","year":"2016","unstructured":"Eklund H, Cadman T, Findon J, et al. Clinical service use as people with attention deficit hyperactivity disorder transition into adolescence and adulthood: a prospective longitudinal study. BMC Health Serv Res. 2016;16:248.","journal-title":"BMC Health Serv Res."},{"key":"808_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/0009922807310938","volume":"47","author":"R Burke","year":"2008","unstructured":"Burke R, Spoerri M, Price A, et al. Survey of primary care pediatricians on the transition and transfer of adolescents to adult health care. Clin Pediatr (Phila). 2008;47:347\u201354.","journal-title":"Clin Pediatr (Phila)."},{"key":"808_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1192\/bjp.bp.107.045245","volume":"194","author":"S McCarthy","year":"2009","unstructured":"McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry. 2009;194:273\u20137.","journal-title":"Br J Psychiatry."},{"key":"808_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eurpsy.2019.01.019","volume":"58","author":"B Libutzki","year":"2019","unstructured":"Libutzki B, Ludwig S, May M, et al. Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis. Eur Psychiatry. 2019;58:38\u201344.","journal-title":"Eur Psychiatry."},{"key":"808_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/1087054719886372","author":"MR Mohammadi","year":"2019","unstructured":"Mohammadi MR, Zarafshan H, Khaleghi A, et al. Prevalence of ADHD and its comorbidities in a population-based sample. J Atten Disord. 2019. https:\/\/doi.org\/10.1177\/1087054719886372 (Epub ahead of print).","journal-title":"J Atten Disord"},{"key":"808_CR27","doi-asserted-by":"publisher","first-page":"e0204516","DOI":"10.1371\/journal.pone.0204516","volume":"13","author":"Q Chen","year":"2018","unstructured":"Chen Q, Hartman CA, Haavik J, et al. Common psychiatric and metabolic comorbidity of adult attention-deficit\/hyperactivity disorder: a population-based cross-sectional study. PLoS ONE. 2018;13:e0204516.","journal-title":"PLoS ONE"},{"key":"808_CR28","doi-asserted-by":"publisher","first-page":"e0132233","DOI":"10.1371\/journal.pone.0132233","volume":"10","author":"E Kirino","year":"2015","unstructured":"Kirino E, Imagawa H, Goto T, et al. Sociodemographics, comorbidities, healthcare utilization and work productivity in Japanese patients with adult ADHD. PLoS ONE. 2015;10:e0132233.","journal-title":"PLoS ONE"},{"key":"808_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12888-017-1463-3","volume":"17","author":"MA Katzman","year":"2017","unstructured":"Katzman MA, Bilkey TS, Chokka PR, et al. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. 2017;17:302.","journal-title":"BMC Psychiatry"},{"key":"808_CR30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1089\/cap.2018.0153","volume":"29","author":"MU Khan","year":"2019","unstructured":"Khan MU, Aslani P. A review of factors influencing the three phases of medication adherence in people with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2019;29:398\u2013418.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"808_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.13206","author":"E Du Rietz","year":"2020","unstructured":"Du Rietz E, Jangmo A, Kuja-Halkola R, et al. Trajectories of healthcare utilization and costs of psychiatric and somatic multimorbidity in adults with childhood ADHD: a prospective register-based study. J Child Psychol Psychiatry. 2020. https:\/\/doi.org\/10.1111\/jcpp.13206.","journal-title":"J Child Psychol Psychiatry."},{"key":"808_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jval.2014.06.002","volume":"17","author":"AA Kawatkar","year":"2014","unstructured":"Kawatkar AA, Knight TK, Moss RA, et al. Impact of mental health comorbidities on health care utilization and expenditure in a large US managed care adult population with ADHD. Value Health. 2014;17:661\u20138.","journal-title":"Value Health."},{"key":"808_CR33","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care."},{"key":"808_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/1471-244X-12-219","volume":"12","author":"S McCarthy","year":"2012","unstructured":"McCarthy S, Wilton L, Murray ML, et al. Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry. 2012;12:219.","journal-title":"BMC Psychiatry"},{"key":"808_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3810\/pgm.2012.09.2591","volume":"124","author":"CB Montano","year":"2012","unstructured":"Montano CB, Young J. Discontinuity in the transition from pediatric to adult health care for patients with attention-deficit\/hyperactivity disorder. Postgrad Med. 2012;124:23\u201332.","journal-title":"Postgrad Med."},{"key":"808_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3810\/pgm.2013.07.2685","volume":"125","author":"A Robb","year":"2013","unstructured":"Robb A, Findling RL. Challenges in the transition of care for adolescents with attention-deficit\/hyperactivity disorder. Postgrad Med. 2013;125:131\u201340.","journal-title":"Postgrad Med."},{"key":"808_CR37","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jaac.2019.06.010","volume":"59","author":"L Ghirardi","year":"2020","unstructured":"Ghirardi L, Larsson H, Chang Z, et al. Attention-deficit\/hyperactivity disorder medication and unintentional injuries in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2020;59:944\u201351.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"808_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/wps.20266","volume":"14","author":"SP Singh","year":"2015","unstructured":"Singh SP, Tuomainen H. Transition from child to adult mental health services: needs, barriers, experiences and new models of care. World Psychiatry. 2015;14:358\u201361.","journal-title":"World Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00808-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00808-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00808-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T08:45:49Z","timestamp":1621845949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00808-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["808"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00808-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"17 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by funding from Shire Development LLC, a member of the Takeda group of companies, Lexington, MA, USA. Open access was funded by Shire Development LLC, a member of the Takeda group of companies, Lexington, MA, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sepehr Farahbakhshian, Daniel S. Barczak, and William Spalding are employees of Takeda Pharmaceuticals USA and hold Takeda stock. Simerpal K. Gill is an employee of Takeda Canada Inc. and holds Takeda stock. Rajeev Ayyagari, Wenxi Tang, Thomas Kulalert, and Madeline Jenkins are employees of Analysis Group, Inc., which was funded by Shire, a member of the Takeda group of companies, to conduct this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not involve prospective data collection; therefore, institutional review board approval was not required. Patient data were deidentified in accordance with the patient confidentiality requirements of the Health Insurance Portability and Accountability Act of 1996. A summary of the final study report was provided to the appropriate regulatory bodies in compliance with appropriate guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available from the IBM<sup>\u00ae<\/sup> MarketScan<sup>\u00ae<\/sup> Commercial Databases, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All authors contributed to the development of the manuscript, reviewed it at each stage of development, and approved the final draft for submission to <i>CNS Drugs<\/i>.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}